<?xml version="1.0" encoding="UTF-8"?>
<p>In efforts to develop a live-attenuated VEEV vaccine for human use [
 <xref ref-type="bibr" rid="B116">116</xref>], the US Army Medical Research Institute of Infectious Diseases in collaboration with the University of North Carolina has introduced mutations into an infectious clone of the TrD IA/B strain [
 <xref ref-type="bibr" rid="B117">117</xref>-
 <xref ref-type="bibr" rid="B120">120</xref>]. The new vaccine candidate, V3526, was shown to be effective in protecting rodent, horses and nonhuman primates against virulent challenge with VEEV IA/B and other related subtypes (e.g., IE, IIA, and IC) [
 <xref ref-type="bibr" rid="B116">116</xref>,
 <xref ref-type="bibr" rid="B120">120</xref>-
 <xref ref-type="bibr" rid="B122">122</xref>].
</p>
